Antiviral therapy for COVID-19

This article reviews data on the incidence of ARVIs and novel coronavirus infection (COVID-19) in the Russian Federation and key antiviral therapies for ARVI and discusses recent published data on the use of various antivirals for COVID-19 treatment, with particular attention to potential biological drug targets. Data from several studies on the broad-spectrum antiviral drug riamilovir are addressed. Riamilovir was found to be highly effective with good tolerability and a favorable safety profile. The range of antiviral activity of riamilovir has significantly expanded over the past few years. In particular, this drug can be used for both the treatment and prevention of COVID-19. Riamilovir was approved by the Russian Ministry of Health not only for ARVI but also for COVID-19 infection and was included in the Clinical Protocol for the inpatient treatment of patients with COVID-19 admitted to Moscow public health system medical institutions. Moreover, riamilovir is also included in the Standard for the diagnosis and treatment of novel coronavirus infection in military personnel of the Armed Forces of the Russian Federation as an etiologic agent of choice for COVID-19 treatment. © 2023, Meditsina-Inform LLC. All rights reserved.

Authors
Larchenko Y.A. , Agapova O.Yu. , Mar'in G.G. , Vakhrushkina O.E. , Kukharenok M.V. , Nistor S.Yu. , Guseva T.F. , Medvedeva E.A. , Zykov K.A.
Journal
Русский медицинский журнал. Медицинское обозрение
Publisher
Общество с ограниченной ответственностью "Русский Медицинский Журнал"
Number of issue
11
Language
Russian
Pages
759-765
Status
Published
Link
External link
DOI
10.32364/2587-6821-2023-7-11-8
Volume
7
Year
2023
Organizations
  • 1 Department of Pulmonology, E.O. Mukhin City Clinical Hospital, 17, Federativnyy av, Moscow, 111399, Russian Federation
  • 2 Department of the of the Faculty Therapy and Occupational Diseases of the N.A. Semashko Scientific Educational Institution of Clinical Medicine, A.I. Yevdokimov Moscow State University of Medicine and Dentistry, 4, Dolgoru-kovskaya str, Moscow, 127006, Russian Federation
  • 3 Department of Epidemiology, RUDN University, 6, Miklukho-Maklaya str, Moscow, 117198, Russian Federation
  • 4 Department of Propaedeutics of Internal Diseases and Gastroenterology, A.I. Yevdokimov Moscow State University of Medicine and Dentistry, 4, Dolgorukovskaya str, Moscow, 127006, Russian Federation
  • 5 RAS, Research Institute of Pulmonology of the Federal Medical Biological Agency of Russia, 28, Orekhovyy blvrd, Moscow, 115682, Russian Federation
Keywords
antiviral therapy; ARVI; COVID-19; influenza; riamilovir; SARS-CoV-2
Cite
ГОСТ MLA RIS BibTex
Share

Other records

MEDIA OF THE FUTURE AND FUTURE CONFLICTS: WHAT CHANGES TO EXPECT WITH THE DEVELOPMENT OF AI TECHNOLOGIES: AN INTERVIEW WITH PROFESSOR KETAN KOTECHA; [МЕДИА БУДУЩЕГО И БУДУЩИЕ КОНФЛИКТЫ: КАКИХИЗМЕНЕНИЙ ЖДАТЬ С РАЗВИТИЕМ ТЕХНОЛОГИЙИСКУССТВЕННОГО ИНТЕЛЛЕКТА: ИНТЕРВЬЮ С ПРОФЕССОРОМКЕТАНОМ КОТЕЧА]

Article
Bulgarova B.A.
Вестник Российского университета дружбы народов. Серия: Литературоведение, журналистика. Федеральное государственное автономное образовательное учреждение высшего образования Российский университет дружбы народов (РУДН). Vol. 28. 2023. P. 842-844

APPLICATION OF AMNIOTIC MEMBRANES IN CLINICAL MEDICINE

Article
Kosova D.A., Aleksandrov L.S., Ishchenko A.I., Trifonova N.S., Nikonov A.P., Lavrentyeva K.I., Ageev M.B., Fedorova E.V., Lyundup A.V., Zholobova M.N., Berishvili M.V., Proklova G.F., Zemlina N.S., Naumenko N.S.
Voprosy Ginekologii, Akusherstva i Perinatologii. Dynasty Publishing House. Vol. 22. 2023. P. 69-78